VRTX Jul 2024 260.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:30AM EDT. Market open.
| Previous close | 2.7100 |
| Open | 2.7100 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 260.00 |
| Expiry date | 2024-07-19 |
| Day's range | 2.7100 - 2.7100 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
ZacksVertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireVertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
LONDON, April 26, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
ZacksThe Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
© 2024 Yahoo. All rights reserved.